Cited by 248Cancer, Hypoxia, and MetabolismCancer, Lipids, and MetabolismMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Metabolic reprogramming in triple-negative breast cancer

Open access

Wang, Zhanyu, Jiang, Qianjin, Dong, Chenfang·2020·Cancer Biology and Medicine

DOI 10.20892/j.issn.2095-3941.2019.0210PMC PMC7142847

Open this paper in CoChat — free account

Abstract

Since triple-negative breast cancer (TNBC) was first defined over a decade ago, increasing studies have focused on its genetic and molecular characteristics. Patients diagnosed with TNBC, compared to those diagnosed with other breast cancer subtypes, have relatively poor outcomes due to high tumor aggressiveness and lack of targeted treatment. Metabolic reprogramming, an emerging hallmark of cancer, is hijacked by TNBC to fulfill bioenergetic and biosynthetic demands; maintain the redox balance; and further promote oncogenic signaling, cell proliferation, and metastasis. Understanding the mechanisms of metabolic remodeling may guide the design of metabolic strategies for the effective intervention of TNBC. Here, we review the metabolic reprogramming of glycolysis, oxidative phosphorylation, amino acid metabolism, lipid metabolism, and other branched pathways in TNBC and explore opportunities for new biomarkers, imaging modalities, and metabolically targeted therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.20892/j.issn.2095-3941.2019.0210

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Metabolic reprogramming in triple-negative breast cancer (TNBC). TNBC upregulates several key glycolytic enzymes and transporters such as GLUT, HK, LDH, and MCT, therefore displaying high rate of glycolysis and glycolytic branched pathways, including serine synthesis and pentose phosphate pathway (PPP) for NADPH generation, and hexosamine biosynthetic pathway (HBP) for protein glycosylation. Other pathways such as fatty acid oxidation (FAO), glutaminolysis and cystine uptake are also induced in TNBC to meet its bioenergetic or biosynthetic demands, and mitigate reactive oxygen species (ROS) that is generated from oxidative phosphorylation (OXPHOS). Enzymes that are upregulated in TNBC are shown as light-yellow ovals, and enzymes downregulated in TNBC are shown as gray ovals.CC BY · PubMed Central

Figure 2 Switchable metabolic dependence on glycolysis and oxidative phosphorylation (OXPHOS) regulated by HIF-1α and AMPK. Under normoxic condition, HIF-1α is hydroxylated and subsequently degraded by PHD2 in an α-KG- and cysteine-dependent manner. In TNBC, decreased levels of α-KG and cysteine due to altered activity of transketolase (TKT) and xCT cystine/glutamate antiporter, respectively, contribute to normoxic activation of HIF-1α signaling, which triggers aerobic glycolysis with the upregulation of glycolysis-related enzymes and transporters. Although TNBC cells rely on glycolysis for rapid proliferation, OXPHOS which generate ATP more efficiently is also required, especially under bioenergetic stress. Activated AMPK and Myc pathways induce mitochondrial biogenesis and enzymes involved in glutaminolysis and fatty acid oxidation (FAO) to facilitate OXPHOS, thus endowing TNBC with metabolic plasticity to switch between glycolysis and OXPHOS. In addition, AMPK signaling also promotes epithelial-mesenchymal transition (EMT) through regulating lipid metabolism and increases the secretion of cytokines to recruit immunosuppressive myeloid-derived suppressor cells (MDSCs). Many drugs have been developed to target these key processes in the metabolic reprogramming of TNBC.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis
Samanta, D., Park, Y., Andrabi, S. A., Shelton, L. M., Gilkes, D. M., & Semenza, G. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0530 · Cited by 242 · cited 1×
“This metabolic reprogramming maintains the level of NADPH to counter hypoxia-or chemotherapy-induced ROS stress and plays a role in BCSC enrichment and lung metastasis 53,54 .”
Background
Retracted
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“…despite the availability of adequate oxygen (known as aerobic glycolysis or the Warburg effect), thereby maintaining high levels of glycolytic intermediates for biosynthetic requirements, while decreasing the production of reactive oxygen species (ROS) from oxidative phosphorylation (OXPHOS) 6 .”
Background
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 2×
“Under normoxic conditions, HIF-1 α is hydroxylated by the proline hydroxylase domain (PHD2; also known as EglN1) in an oxygen-and α -ketoglutarate ( α -KG)- dependent manner, which results in its ubiquitination and subsequent degradation 15 .”
Background
Triple-Negative Breast Cancer
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,719
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thurlimann, B. J. K., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 1×
“This rewired metabolic network depends on the dysregulation of many key enzymes, such as pyruvate kinase muscle isozyme M2 (PKM2), which redirects glycolytic intermediates into the anabolic pathway 7 .”
Background
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892 · cited 1×
“Nevertheless, chemotherapy currently remains the mainstay of systemic treatment due to the lack of effective targeted therapy such as anti-HER2 and anti-ER 5 .”
Background
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“EMT confers TNBC with cancer stem cell (CSC)-like characteristics, including elevated metastatic potential and enhanced resistance to chemotherapy 4 .”
Background
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119

Show all 135 references

Sorted by citations

Glucose Metabolism and Glucose Transporters in Breast Cancer
Shin, E., & Koo, J. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.728759 · Cited by 172
LOX-1 and cancer: an indissoluble liaison
Murdocca, M., Masi, C. D., Pucci, S., Mango, R., Novelli, G., Natale, C. D., & Sangiuolo, F. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00279-0 · Cited by 121
The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities
Sabit, H., Adel, A., Abdelfattah, M. M., Ramadan, R. M., Nazih, M., Abdel-Ghany, S. E., El-Hashash, A. H. K., & Arneth, B. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217865 · Cited by 110
The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
He, L., Wick, N., Germans, S. K., & Peng, Y. S. (2021) · Cancers · doi:10.3390/cancers13246209 · Cited by 89
Immature natural killer cells promote progression of triple-negative breast cancer
Thacker, G., Henry, S., Nandi, A., Debnath, R., Singh, S., Nayak, A., Susnik, B., Boone, M., Zhang, Q. H., Kesmodel, S. B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abl4414 · Cited by 88
Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect
Shi, Y., Zhang, Y., Ran, F., Liu, J., Lin, J., Hao, X., Ding, L., & Ye, Q. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.012 · Cited by 83
Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling
Han, B., Zhang, H., Tian, R., Liu, H., Wang, Z., Wang, Z., Tian, J., Cui, Y., Ren, S., Zuo, X., et al. (2022) · Theranostics · doi:10.7150/thno.72404 · Cited by 84
Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy
Liu, Q., Guan, C., Liu, C., Li, H., Wu, J., & Sun, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113861 · Cited by 86
Oncogene-mediated metabolic gene signature predicts breast cancer outcome
Aslan, M., Hsu, E., Garcia-Marques, F. J., Bermudez, A., Liu, S., Shen, M., West, M., Zhang, C. A., Rice, M. A., Brooks, J. D., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00341-6 · Cited by 68
Updated incidence of neurological deficits following insular glioma resection: A systematic review and meta-analysis
Lu, V. M., Goyal, A., Quiñones‐Hinojosa, A., & Chaichana, K. L. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.12.013 · Cited by 54
Expanding Roles of De Novo Lipogenesis in Breast Cancer
Simeone, P., Tacconi, S., Longo, S., Lanuti, P., Bravaccini, S., Pirini, F., Ravaioli, S., Dini, L., & Giudetti, A. M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073575 · Cited by 55
Energy metabolism pathways in breast cancer progression: The reprogramming, crosstalk, and potential therapeutic targets
Zheng, X., Ma, H., Wang, J., Huang, M., Fu, D., Qin, L., & Yin, Q. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101534 · Cited by 59
Correlation between the Warburg effect and progression of triple-negative breast cancer
Liu, S., Li, Y., Yuan, M., Song, Q., & Liu, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1060495 · Cited by 58
Recent progress in immune evasion mechanisms of triple-negative breast cancer
Yang, Y., & Wang, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07370-w · Cited by 56
Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer
Umar, S. M., Kashyap, A., Kahol, S., Mathur, S. R., Gogia, A., Deo, S. V. S., & Prasad, C. P. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112282 · Cited by 48
Biomimetic multifunctional nanodrugs enable regulating abnormal tumor metabolism and amplifying PDT-induced immunotherapy for synergistically enhanced tumor ablation
Liu, Y., Wu, H., Wang, S., Zhang, X., Gong, L., Xiao, C., Liu, C., Chen, L., Zhao, H., Liu, C., et al. (2023) · Materials Today · doi:10.1016/j.mattod.2023.07.003 · Cited by 47
Lactylproteome analysis indicates histone H4K12 lactylation as a novel biomarker in triple-negative breast cancer
Cui, Z., Li, Y., Lin, Y., Zheng, C., Luo, L., Hu, D., Chen, Y., Xiao, Z., & Sun, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1328679 · Cited by 47
Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
Munkácsy, G., Santarpia, L., & Győrffy, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086945 · Cited by 46
“Glycolysis is more important in TNBC (Figure 3) than in other subtypes of breast cancer, as it is characterized by increased glucose uptake and lactate secretion [63].”
Background
Glutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3β/β-catenin/EMT pathway
Tan, Z., Boyapati, K., Tressler, C. M., Jenkinson, N. M., & Glunde, K. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216653 · Cited by 46
Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities
Kohan, R., Collin, A., Guizzardi, S., de Talamoni, N. T., & Picotto, G. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04103-2 · Cited by 45
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Kumar, M. A., Baba, S. K., Khan, I. R., Khan, M. S., Husain, F. M., Ahmad, S., Haris, M., Singh, M., Akil, A. A., Macha, M. A., et al. (2025) · MedComm · doi:10.1002/mco2.70120 · Cited by 52
HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple‐negative breast cancer
Guo, X., Wang, A., Wang, W., Wang, Y., Chen, H., Liu, X., Xia, T., Zhang, A., Chen, D., Qi, H., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12856 · Cited by 44
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 41
“…conversion of glutamate into α -KG by positively regulating GDH, glutamate oxaloacetate transaminase (GOT), and ornithine aminotransferase (OAT) [278]. c-Myc-dependent glutamine catabolism replenishes intermediate metabolites of the TCA cycle by producing the anaplerotic substrate α -KG, but…”
Background
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer
Jan, A., Sofi, S., Jan, N., & Mir, M. A. (2025) · Future Oncology · doi:10.1080/14796694.2025.2461443 · Cited by 41
Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer
Wang, Y., Sun, Y., Wang, F., Wang, H., & Hu, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115866 · Cited by 37
Metabolic Flexibility Is a Determinant of Breast Cancer Heterogeneity and Progression
Fukano, M., Park, M., & Deblois, G. (2021) · Cancers · doi:10.3390/cancers13184699 · Cited by 36
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova, V., Longhin, E., Pilalis, E., Mastrokalou, C., Miklikova, S., Cihova, M., Poturnayova, A., Mackova, K., Babelova, A., Trnkova, L., et al. (2022) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2022.112662 · Cited by 25
The Molecular Mechanisms behind Advanced Breast Cancer Metabolism: Warburg Effect, OXPHOS, and Calcium
Mitaishvili, E., Feinsod, H., David, Z., Shpigel, J., Fernandez, C., Sauane, M., & de la Parra, C. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2903099 · Cited by 34
An Arthropod Hormone, Ecdysterone, Inhibits the Growth of Breast Cancer Cells via Different Mechanisms
Shuvalov, O., Fedorova, O., Tananykina, E., Gnennaya, Y., Daks, A., Petukhov, A., & Barlev, N. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.561537 · Cited by 30
Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Cervical Cancer
Shi, X., Wang, J., Dai, S., Qin, L., Zhou, J., & Chen, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s280690 · Cited by 30
Circular RNA‐associated ceRNA network involved in HIF‐1 signalling in triple‐negative breast cancer: circ_0047303 as a potential key regulator
Darbeheshti, F., Mahdiannasser, M., Noroozi, Z., Firoozi, Z., Mansoori, B., Daraei, A., Bastami, M., Nariman‐Saleh‐Fam, Z., Valipour, E., & Mansoori, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17066 · Cited by 29
PRMT3 regulates the progression of invasive micropapillary carcinoma of the breast
Zhi, R., Wu, K., Zhang, J., Liu, H., Niu, C., Li, S., & Fu, L. (2023) · Cancer Science · doi:10.1111/cas.15724 · Cited by 28
Fibroblast Growth Factor Receptor 4 Promotes Triple‐Negative Breast Cancer Progression via Regulating Fatty Acid Metabolism Through the AKT/RYR2 Signaling
Ye, J., Wu, S., Quan, Q., Ye, F., Zhang, J., Song, C., Fan, Y., Cao, H., Tang, H., & Zhao, J. (2024) · Cancer Medicine · doi:10.1002/cam4.70439 · Cited by 27
Cuproptosis in cancers: Function and implications from bench to bedside
Huang, X.-Y., Shen, J.-Y., Huang, K., Wang, L., Sethi, G., & Ma, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116874 · Cited by 26
Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Poddar, A., Rao, S. R., Prithviraj, P., Kannourakis, G., & Jayachandran, A. (2022) · Current Oncology · doi:10.3390/curroncol29100540 · Cited by 24
“Interestingly, OXPHOS activity in TNBC is reported to be both increased as well as reduced [19,43].”
Background
Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer
Inaishi, T., Shibata, M., Ichikawa, T., Kanda, M., Hayashi, M., Soeda, I., Takeuchi, D., Takano, Y., Tsunoda, N., Kodera, Y., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8220 · Cited by 23
Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer
Zhang, J., Chen, X., Chen, G., Wang, H., Jia, L., Yue, H., & Yao, D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126348 · Cited by 24
Histone lactylation bridges metabolic reprogramming with chromatin-immune crosstalk in triple-negative breast cancer
Li, J., Li, Z., Zhang, H., Zhang, H., Tang, Y., Tang, Y., Guo, S., Ye, T., Wang, J., & Li, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218227 · Cited by 22
Mitochondrial Redox Vulnerabilities in Triple-Negative Breast Cancer: Integrative Perspectives and Emerging Therapeutic Strategies
Cruz‐Gregorio, A. (2026) · Metabolites · doi:10.3390/metabo16010060 · Cited by 24
“This reprogramming metabolic overexpresses glucose transporters such as glucose transporter 1, increasing glucose internalization and its entry into glycolysis [1].”
SLC7A5/E2F1/PTBP1/PKM2 axis mediates progression and therapy effect of triple-negative breast cancer through the crosstalk of amino acid metabolism and glycolysis pathway.
Jiang, C.-F., Qian, Y.-C., Bai, X., Li, S., Zhang, L., Xie, Y.-X., Lu, Y.-F., Lu, Z.-M., Liu, B., & Jiang, B. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217612 · Cited by 22
Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer
Schreier, A., Zappasodi, R., Serganova, I. S., Brown, K. A., Demaria, S., & Andreopoulou, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1061789 · Cited by 23
“In addition, studies have shown that there is significant heterogeneity in the metabolic dependencies and preferences between TNBC tumors (19, 55, 62).”
Background
Breaking barriers: Engineering extracellular vesicles for enhanced endosomal escape and therapeutic delivery
Kim, J., Hwang, Y. H., Nam, G., & Kim, I.-S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114462 · Cited by 27
SIPA1 Enhances Aerobic Glycolysis Through HIF-2α Pathway to Promote Breast Cancer Metastasis
Yao, C., Weng, J., Feng, L., Zhang, W., Xu, Y. K., Zhang, P., Tanaka, Y., & Su, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.779169 · Cited by 20
Unlocking apoptosis in triple negative breast cancer: Harnessing “glutamine trap” to amplify the efficacy of lapatinib-loaded mixed micelles
Ghadi, R., Kuche, K., Date, T., Bhargavi, N., Chaudhari, D., & Jain, S. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.213822 · Cited by 19
Unveiling the impact of lipid metabolism on triple-negative breast cancer growth and treatment options
Cai, X.-X., Zhang, Z.-Z., Yang, X., Shen, W.-R., Yuan, L.-W., Ding, X., Yu, Y., & Cai, W.-Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1579423 · Cited by 18
“TNBC cells demonstrate metabolic plasticity to overcome nutrient scarcity, acquiring stromal-derived fuels to sustain proliferation, drive chemoresistance, and remodel the immunosuppressive microenvironment (10).”
Lactylation in cancer: molecular mechanisms and advances in clinical study
Li, J., Miao, C., Guo, H., Lin, M., Chen, R., Peng, J., Wang, J., Tang, C., & Chen, Z. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02573-1 · Cited by 21
“…relationships and their effector consequences with orthogonal perturbations, and mapping heterogeneity through cross-cohort Kla–subtype atlases that connect MCT1/MCT4 balance, LDH isoforms, and lactylation fingerprints to clinically actionable subgroups and companion diagnostics [78, 88, 393, 394].”
Glycometabolic rearrangements–aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential
Zhang, Z., & Zhang, H. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2015321 · Cited by 18
“cancer [21], gastric cancer [22], prostate cancer [23], and lung cancer [24].”
Background
Integrated network pharmacology and serum metabolomics approach deciphers the anti-colon cancer mechanisms of Huangqi Guizhi Wuwu Decoction
Pan, B., Xia, Y., Fang, S., Ai, J., Wang, K., Zhang, J., Du, C., Chen, Y., Liu, L., & Yan, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1043252 · Cited by 18
Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes
Malayil, R., Chhichholiya, Y., Vasudeva, K., Singh, H. V., Singh, T., Singh, S., & Munshi, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02037-2 · Cited by 19
The role of metabolic reprogramming in immune escape of triple-negative breast cancer
Bao, R., Qu, H., Li, B., Cheng, K., Miao, Y., & Wang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424237 · Cited by 22
“…(13, 14), enabling tumor cells to meet the energy demands and biosynthetic requirements necessary for malignant proliferation, maintain redox homeostasis, proliferate rapidly in a nutrient-de ﬁ cient tumor microenvironment (15), and facilitate the survival and metastasis of cancer cells (16).”
Background
Nuances of PFKFB3 Signaling in Breast Cancer
Galindo, C. M., Ganzella, F. A. D. O., Klassen, G., Ramos, E. A. D. S., & Acco, A. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.01.002 · Cited by 17
LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer
Cisneros-Villanueva, M., Fonseca-Montaño, M. A., Ríos-Romero, M., López‐Camarillo, C., Jiménez‐Morales, S., Langley, E., Rosette-Rueda, A. S., Cedro‐Tanda, A., Hernández‐Sotelo, D., & Hidalgo‐Miranda, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-51947-2 · Cited by 17
“This may be due to the epidemiological finding that TNBC primarily affects young, premenopausal women between the ages of 40 and 46, who make up about 15–20% of all breast cancer patients 36,37 .”
Background
Mitochondrial inhibitors: a new horizon in breast cancer therapy
Yan, Y., Li, S., Su, L., Tang, X., Chen, X., Gu, X., Yang, G., Chi, H., & Huang, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1421905 · Cited by 16
Advanced progress of spatial metabolomics in head and neck cancer research
Zhao, H., Shi, C., Han, W., Luo, G., Huang, Y., Fu, Y., Lu, W., Hu, Q., Shang, Z., & Yang, X. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100958 · Cited by 15
“This metabolic shift leads to altered pathways, ensuring adequate ATP production for survival and rapid proliferation in the nutrient-deprived tumor microenvironment, thus facilitating tumor occurrence and progression [24].”
Background
The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma
Su, Z., Wang, C., Pan, R., Li, H., Chen, J., Tan, J., Tian, X., Lin, T., & Shen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1028263 · Cited by 14
“In breast cancer, notably, the inhibition of glycolysis promotes the transformation of the breast cancer stem cells from a quiescent, mesenchymal-like state to an epithelial-like state, referred to as epithelial-mesenchymal transition (6).”
Background
Mitochondria-targeted photosensitizer based nanoplatform loading glutathione inhibitor for enhanced breast cancer photodynamic therapy
Huang, Z., Li, D., Guo, F., Xian, T., Hu, H.-S., Xu, J., Luo, Y., Chen, Z., Wang, B., & Zhang, Y. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112956 · Cited by 14
MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells
Yamashita, N., Withers, H. G., Morimoto, Y., Bhattacharya, A., Haratake, N., Daimon, T., Fushimi, A., Nakashoji, A., Thorner, A. R., Isenhart, E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108168 · Cited by 14
The determinants of metabolic discrepancies in aerobic glycolysis: Providing potential targets for breast cancer treatment
Littleflower, A. B., Parambil, S. T., Antony, G. R., & Subhadradevi, L. (2024) · Biochimie · doi:10.1016/j.biochi.2024.01.003 · Cited by 14
Disarib, a Specific BCL2 Inhibitor, Induces Apoptosis in Triple-Negative Breast Cancer Cells and Impedes Tumour Progression in Xenografts by Altering Mitochondria-Associated Processes
Manjunath, M., Ravindran, F., Sharma, S., Siddiqua, H., Raghavan, S. C., & Choudhary, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126485 · Cited by 14
“TNBC cells possess a hybrid metabolic status having high glycolysis and a considerable level of oxidative phosphorylation (OXPHOS), including HIF-1/AMPK signalling [11].”
Background
Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Compassion of MCF7 and MDA-MB-231 Cancer Cell LinesPreprint
San-Millán, I., Martinez, J. L., Pickard, S. L., Yu, H., Hirsch, F. R., Rivard, C. J., & Brooks, G. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.23.533060 · Cited by 14
Renal-clearable and tumor-retained nanodots overcoming metabolic reprogramming to boost mitochondrial-targeted photodynamic therapy in triple-negative breast cancer
Yao, D., Wang, Y., Dong, X., Chen, Y., Ji, D., Zou, R., Huang, Y., Huang, W., & Wang, D. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03264-7 · Cited by 14
“This process contributes to the formation of an acidic tumor microenvironment (TME) [4].”
Metabolic Adaptations in Cancer Progression: Optimization Strategies and Therapeutic Targets
Dominiak, A., Chełstowska, B., & Nowicka, G. (2025) · Cancers · doi:10.3390/cancers17142341 · Cited by 15
“Studies suggest that metastatic tumors, especially in lipid-rich environments such as the bone marrow or adipose tissue, exhibit enhanced FAO to support their survival and proliferation [61,74].”
Enhanced Water Solubility and Anti-Tumor Activity of Oleanolic Acid through Chemical Structure Modification
Gu, Z., Lin, S., Yan, W., Chen, D., Zeng, Z., Chen, L., Li, Y., & He, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113291 · Cited by 13
Hyperglycemia and O-GlcNAc transferase activity drive a cancer stem cell pathway in triple-negative breast cancer
Ayodeji, S. A., Bao, B., Teslow, E. A., Polin, L., Dyson, G. E., Bollig-Fischer, A. B., & Fehl, C. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02942-6 · Cited by 13
“One aspect of this link could be metabolic reprograming in TNBC tumors [66].”
Background
Targeting cancer stem cell plasticity in triple-negative breast cancer
Guo, Z., & Han, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00190 · Cited by 18
METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer
Yuan, X., Shao, Y.-C., Guan, X.-Q., Liu, Q., Chu, M.-F., Yang, Z., Li, H., Zhao, S., Tian, Y., Zhang, J., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119716 · Cited by 13
Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC)
Sunassee, E. D., Jardim‐Perassi, B. V., Madonna, M. C., Ordway, B., & Ramanujam, N. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-1004 · Cited by 13
Carrier-free nanomedicines self-assembled from palbociclib dimers and Ce6 for enhanced combined chemo-photodynamic therapy of breast cancer
Huang, Z., Hu, H., Xian, T., Xu, Z., Tang, D., Wang, B., & Zhang, Y. (2023) · RSC Advances · doi:10.1039/d2ra05932k · Cited by 14
Construction and validation of a metabolic-related genes prognostic model for oral squamous cell carcinoma based on bioinformatics
Zhang, J., Ma, C., Qin, H., Wang, Z., Zhu, C., Liu, X., Hao, X., Liu, J., Li, L., & Cai, Z. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01417-3 · Cited by 12
“Changes in metabolic processes are closely related to tumor growth [12–15].”
Background
Metabolic Alterations in Canine Mammary Tumors
Tamarindo, G. H., Novais, A. A., Chuffa, L. G. D. A., & Zuccari, D. A. P. D. C. (2023) · Animals · doi:10.3390/ani13172757 · Cited by 14
Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer
Tan, Z., Deme, P., Boyapati, K., Claes, B. S. R., Duivenvoorden, A. A. M., Heeren, R. M. A., Tressler, C. M., Haughey, N. J., & Glunde, K. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01742-0 · Cited by 12
“…TNBC subtype, which could lead to the development of novel molecular targets, are critically important for improving therapeutic options for treating TNBC. Metabolic reprogramming is a hallmark of cancer and has provided promising therapeutic targets for the treat-ment of breast cancer [10].”
Background
Nucleic acid vaccines‐based therapy for triple‐negative breast cancer: A new paradigm in tumor immunotherapy arena
Saleh, R. O., Ibrahim, F. M., Pallathadka, H., Kaur, I., Ahmad, I. S., Ali, S. H. J., Redhee, A. H., Ghildiyal, P., Jawad, M. A., & Alsaadi, S. B. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3992 · Cited by 11
“20,21 As a result, several signaling pathways play crucial roles in the development of malignancy.”
Background
In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancer
Corrado, A., Lorito, N., Anemone, A., Carella, A., Villano, D., Pirotta, E., Gammaraccio, F., Subbiani, A., Bacci, M., Dastrù, W., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02065-y · Cited by 12
“The development of breast cancer is characterized by a multistep progression that is strongly influenced by tumor metabolic reprogramming [2].”
Delayed breast reconstruction with tram-flap and various modifications after radical mastectomy
Smolanka, I. I., Bagmut, I. Y., Sheremet, M. I., Lyashenko, A. O., Movchan, O. V., Smolanka, I. I., Loboda, A. D., Kolisnyk, I. L., Sydorchuk, L., & Lazaruk, O. V. (2021) · Journal of Medicine and Life · doi:10.25122/jml-2021-0354 · Cited by 12
Artificial Diets with Selective Restriction of Amino Acids and Very Low Levels of Lipids Induce Anticancer Activity in Mice with Metastatic Triple-Negative Breast Cancer
Guillén-Mancina, E., Jiménez‐Alonso, J. J., Calderón‐Montaño, J. M., Jiménez-González, V., Díaz-Ortega, P., Burgos‐Morón, E., & López‐Lázaro, M. (2023) · Cancers · doi:10.3390/cancers15051540 · Cited by 12
A gold-based inhibitor of oxidative phosphorylation is effective against triple negative breast cancer
Mertens, R. T., Kim, J. H., Ofori, S., Olelewe, C., Kamitsuka, P. J., Kwakye, G. F., & Awuah, S. G. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116010 · Cited by 11
Targeting metabolism of breast cancer and its implications in T cell immunotherapy
Zou, J., Mai, C., Lin, Z., Zhou, J., & Lai, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1381970 · Cited by 15
Surgical treatment for insular gliomas. A systematic review and meta-analysis on behalf of the EANS neuro-oncology section
Simon, M., Hagemann, A., Gajadin, S., Signorelli, F., & Vincent, A. J. P. E. (2024) · Brain and Spine · doi:10.1016/j.bas.2024.102828 · Cited by 11
“…et al., 2021; Li et al., 2020; Moshel et al., 2008; ¨ et al., 2003; Pallud et al., 2021; Pitskhelauri et al., 2021; Rao et al., 2018; Rossi et al., 2021; Sanai et al., 2010; Simon et al., 2009; Skrap et al., 2012; Sughrue et al., 2017; Wang et al., 2012; Wang et al., 2017; Zhuang et al., 2016).”
BackgroundMethodInfluential
Lipid dysregulation in triple negative breast cancer: Insights from mass spectrometry-based approaches
Huang, X., Ali, A., Yachioui, D. E., Dévédec, S. E. L., & Hankemeier, T. (2025) · Progress in Lipid Research · doi:10.1016/j.plipres.2025.101330 · Cited by 12
Metabolic heterogeneity in TNBCs: A potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy
Samuel, S. M., Varghese, E., Satheesh, N. J., Triggle, C. R., & Büsselberg, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114911 · Cited by 14
“TNBCs maintain a significantly high glycolytic flux to support their proliferation and survival [5].”
Oncogenic roles of lncRNA BLACAT1 and its related mechanisms in human cancers
Han, W., Fan, Y., & Guan, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110632 · Cited by 11
Network-based approach elucidates critical genes in BRCA subtypes and chemotherapy response in triple negative breast cancer
Agrawal, P., Jain, N., Gopalan, V., Timon, A., Singh, A., Rajagopal, P. S., & Hannenhalli, S. S. (2024) · iScience · doi:10.1016/j.isci.2024.109752 · Cited by 9
Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis
Zhai, X., Mao, L., Kang, Q., Liu, J., Zhou, Y., Wang, J., Yang, X., Wang, D., Wang, J., Li, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.010 · Cited by 10
Cancer-associated fibroblasts secrete CSF3 to promote TNBC progression via enhancing PGM2L1-dependent glycolysis reprogramming
Qin, W., Chen, B., Li, X., Zhao, W., Wang, L., Zhang, N., Wang, X., Luo, D., Liang, Y., Li, Y., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07580-6 · Cited by 10
Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
Xi, Y., Li, T., Xi, Y., Zeng, X., Miao, Y., Guo, R., Zhang, M., & Li, B. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02681-0 · Cited by 10
Triple-negative breast cancer treatment meets nanoparticles: Current status and future direction
Shokooh, M. K., Emami, F., Duwa, R., Jeong, J., & Yook, S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103274 · Cited by 10
ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability
Reddi, K. K., Chava, S., Chabattula, S. C., Edwards, Y. J. K., Singh, K., & Gupta, R. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06831-2 · Cited by 9
“The treatment conditions are described in the corresponding ﬁ gure legends.”
Metabolic reprogramming in the pathogenesis and progression of nasopharyngeal carcinoma: molecular mechanisms and therapeutic implications.
Wang, H.-L., Hu, J.-D., Zhou, W.-B., & Qian, A.-J. (2024) · American Journal of Cancer Research · doi:10.62347/vyat9271 · Cited by 8
Mechanism of the Warburg effect and its role in breast cancer immunotherapy
Saheed, E. S., Aromolaran, R. F., Atoyebi, A. D., Adeleke, F. C., Otuyalo, A. I., & Edozie, P. K. (2024) · Discover Medicine · doi:10.1007/s44337-024-00131-6 · Cited by 10
USP35 promotes breast cancer progression by regulating PFK-1 ubiquitination to mediate glycolysis
Lian, W., Hong, C., Chen, D., & Wang, C. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00733.2024 · Cited by 9
Erigoster B targeting DECR1 induces ferroptosis of breast cancer cells via promoting phosphatidylcholine/arachidonic acid metabolism
Yang, Z., Yin, S., Yi, Z., Li, Y., Wu, S., Xu, P., Tang, M., Sun, Y., Qi, H., Zhang, F., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00945-2 · Cited by 11
“Metabolic reprogramming is not only a hallmark of tumors but also provides a promising opportunity for BC treatment 22,23 .”
Targeting Mitochondrial Quality Control for the Treatment of Triple-Negative Breast Cancer: From Molecular Mechanisms to Precision Therapy
Pei, W., Dai, L., Li, M., Cao, S., Xiao, Y., Yang, Y., Ma, M., Deng, M., Mo, Y., & Liu, M. (2025) · Biomolecules · doi:10.3390/biom15070970 · Cited by 10
Evaluating chemotherapeutic potential of soya-isoflavonoids against high penetrance genes in triple-negative breast cancer
Chatterjee, P., & Banerjee, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2243352 · Cited by 10
“Hence the mainstay treatment strategy in TNBC remains constricted to mastectomy, chemotherapy and radiation techniques (Wang et al., 2020).”
The Role of Amino Acids in the Diagnosis, Risk Assessment, and Treatment of Breast Cancer: A Review
Bel’skaya, L. V., Gundyrev, I. A., & Solomatin, D. V. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090474 · Cited by 12
Carboxypeptidase N1 is anticipated to be a synergy metrics for chemotherapy effectiveness and prognostic significance in invasive breast cancer
Cui, R., Wang, C., Li, T., Hua, J., Zhao, T., Ren, L., Wang, Y., & Li, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02256-5 · Cited by 9
The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors
Vetrano, I. G., Dei, M., Nazzi, V., Eoli, M., Innocenti, N., Saletti, V., Potenza, A., Carrozzini, T., Pollaci, G., Gorla, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010061 · Cited by 9
Cystine/cysteine metabolism regulates the progression and response to treatment of triple‑negative breast cancer (Review)
Xiao, W., & Xu, C. (2024) · Oncology Letters · doi:10.3892/ol.2024.14654 · Cited by 8
Hypoxia‑induced SREBP1‑mediated lipogenesis and autophagy promote cell survival via fatty acid oxidation in breast cancer cells
Jung, J., Yang, Y., & Kim, Y. (2025) · Oncology Letters · doi:10.3892/ol.2025.14921 · Cited by 8
A Spectroscopic Technique to Simultaneously Characterize Fatty Acid Uptake, Mitochondrial Activity, Vascularity, and Oxygen Saturation for Longitudinal Studies In Vivo
Deutsch, R. J., D’Agostino, V. W., Sunassee, E. D., Kwan, M. H.-W., Madonna, M. C., Palmer, G. M., Crouch, B. T., & Ramanujam, N. (2022) · Metabolites · doi:10.3390/metabo12050369 · Cited by 8
ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer
Zhang, H., Gao, A., Liu, Q., Zhang, F., Wang, S., Chen, X., Shi, W., Zhang, Y., Liu, Q., Zheng, Y., et al. (2023) · Journal of Cell Science · doi:10.1242/jcs.260964 · Cited by 8

Authors: Wang, Z., Jiang, Q., & Dong, C.
Affiliations: Second Affiliated Hospital of Zhejiang University (CN)
Zhejiang University (CN)
Corresponding author: Dong, Chenfang
ORCID: Wang, Zhanyu
Dong, Chenfang
Venue: Cancer Biology and Medicine
Publisher: China Anti-cancer Association
Published: 2020
Volume: 17
Issue: 1
Pages: 44-59
ISSN: 2095-3941 (ISSN-L)
DOI: 10.20892/j.issn.2095-3941.2019.0210
PMC: PMC7142847
OpenAlex: W3020548503
Cited by: 248
References: 135
Citations by year: 2026: 61 · 2025: 63 · 2024: 46 · 2023: 31 · 2022: 20 · 2021: 18 · 2020: 8
FWCI: 6.58
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Cancer Biology and Medicine (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: triple-negative breast cancer, metabolic reprogramming, glycolysis, oxidative phosphorylation, amino acid metabolism, lipid metabolism, redox homeostasis, oncogenic signaling, metastasis, metabolic biomarkers, metabolic imaging
MeSH terms: Warburg Effect, Oncologic, Amino Acids, Antineoplastic Agents, Female, Humans, Oxidative Phosphorylation, Biomarkers, Tumor, Lipid Metabolism, Molecular Targeted Therapy, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolic reprogramming in triple-negative breast cancer

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks